Zacks Investment Research Upgrades MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) to Buy

Zacks Investment Research upgraded shares of MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (NYSEARCA:MOR) from a hold rating to a buy rating in a research report sent to investors on Friday morning, Zacks.com reports. Zacks Investment Research currently has $37.00 price objective on the stock.

According to Zacks, “MorphoSys AG is a biopharmaceutical company. It develops treatment for cancer, inflammations and autoimmune diseases. The company’s proprietary portfolio consists of MOR208, MOR202, MOR103, MOR106 and MOR107. Its partnered programs lighthouse project includes Tremfya(R) and Gantenerumab. MorphoSys AG is based in Planegg, Germany. “

Separately, Guggenheim assumed coverage on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 in a research note on Wednesday, November 27th. They set a buy rating for the company.

Shares of MOR stock opened at $32.88 on Friday. The stock has a 50-day simple moving average of $34.76 and a 200 day simple moving average of $29.94. MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 has a fifty-two week low of $22.46 and a fifty-two week high of $37.96.

Featured Article: What is the Euro STOXX 50 Index?

Get a free copy of the Zacks research report on MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 and related companies with MarketBeat.com's FREE daily email newsletter.